To amend the Federal Food, Drug, and Cosmetic Act to authorize a 6-month extension of certain exclusivity periods in the case of approved drugs that are subsequently approved for a new indication to prevent, diagnose, or treat a rare disease or condition, and for other purposes.
The bill’s titles are written by its sponsor.
Feb 13, 2015
114th Congress, 2015–2017
Died in a previous Congress
This bill was introduced on February 13, 2015, in a previous session of Congress, but was not enacted.
Representative for Florida's 12th congressional district
Read Text »
Last Updated: Feb 13, 2015
Length: 11 pages
Earlier Version — Introduced
This activity took place on a related bill, H.R. 5750 (113th).
H.R. 971 (114th) was a bill in the United States Congress.
How to cite this information.
Civic Impulse. (2017). H.R. 971 — 114th Congress: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015. Retrieved from https://www.govtrack.us/congress/bills/114/hr971
“H.R. 971 — 114th Congress: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015.” www.GovTrack.us. 2015. June 26, 2017 <https://www.govtrack.us/congress/bills/114/hr971>
|title=H.R. 971 (114th)
|accessdate=June 26, 2017
|author=114th Congress (2015)
|date=February 13, 2015
|quote=Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015